Literature DB >> 8791032

Response in chronic schizophrenia correlated with chlorpromazine, 7-OH-chlorpromazine and chlorpromazine sulfoxide levels.

M Chetty1, V L Pillay, S V Moodley, R Miller.   

Abstract

The relationship between chlorpromazine, six of its metabolites and therapeutic response in chronic schizophrenic patients was investigated in this study. Logistic regression revealed no correlation between therapeutic response and four metabolites viz. Nor1 chlorpromazine, Nor2 chlorpromazine, chlorpromazine-N-oxide and Nor2 chlorpromazine sulfoxide. A good correlation was seen between CPZ (P = 0.036), 7-hydroxychlorpromazine (P = 0.004), chlorpromazine sulfoxide (P = 0.002) and therapeutic response. Good therapeutic response was correlated to high levels of chlorpromazine and its 7-hydroxy metabolite while high levels of the sulfoxide metabolite appeared to have a negative effect on therapeutic response. Poor responders who had high levels of chlorpromazine also had high levels of the sulfoxide metabolite. This suggests that the difference in response may lie in the difference in the metabolism of the drug.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8791032     DOI: 10.1016/0924-977x(95)00047-s

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  3 in total

1.  Negative effects of chronic oral chlorpromazine and olanzapine treatment on the performance of tasks designed to assess spatial learning and working memory in rats.

Authors:  A V Terry; S E Warner; L Vandenhuerk; A Pillai; S P Mahadik; G Zhang; M G Bartlett
Journal:  Neuroscience       Date:  2008-08-27       Impact factor: 3.590

2.  Chronic antipsychotic treatment: protracted decreases in phospho-TrkA levels in the rat hippocampus.

Authors:  Alvin V Terry; Debra A Gearhart; Anilkumar Pillai; Guodong Zhang; Michael G Bartlett
Journal:  Int J Neuropsychopharmacol       Date:  2010-01-11       Impact factor: 5.176

3.  Atypical antipsychotics as noncompetitive inhibitors of alpha4beta2 and alpha7 neuronal nicotinic receptors.

Authors:  Vladimir P Grinevich; Roger L Papke; Patrick M Lippiello; Merouane Bencherif
Journal:  Neuropharmacology       Date:  2009-05-28       Impact factor: 5.250

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.